Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tigecycline for Resistant Gram-negative Infections
NCT00079989Phase 3Completed
- Sponsor
- Pfizer
- Start
- Dec 2003
- Primary completion
- Nov 2005
- Modality
- Orthosteric Ligands
01
Overview
A Phase 3 trial of tigecycline in Gram-negative bacterial infection, Intra-abdominal infection (IAI), Skin and Skin Structure Infection (SSSI), community acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), sponsored by Pfizer. Started Dec 2003; status: completed.
02
Drugs
tigecycline
03
Conditions
Gram-negative bacterial infectionIntra-abdominal infection (IAI)Skin and Skin Structure Infection (SSSI)community acquired pneumonia (CAP)hospital-acquired pneumonia (HAP)
Beyond the preview
Go deeper on NCT00079989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00079989.